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Background: Antibodies against cardiolipin (aCL) are associated with increased risk of cardiovascular disease (CVD).
We here determine the role of antibodies against oxidized CL (aOxCL).
Methods: One third of sixty-year olds from the Stockholm County were screened (2039 men, 2193 women), where
211 incident CVD-cases and 633 age- and sex-matched controls were identified (5–7 year follow-up). Antibodies
were determined by ELISA and uptake of oxLDL in macrophages by FACScan.
Results: IgM aOxCL was lower among CVD cases than controls (p=0.024). aOxCL-levels were divided in quartiles
with the highest quartile set as the reference group. After adjustment for smoking, BMI, type II diabetes,
hypercholesterolaemia and hypertension, an increased risk was determined in the lowest quartile of IgM aOxCL (OR:
1.80, CI: 1.12–2.91, p=0.0159); OR for men in the lowest quartile was 2.46 (CI 1.34–4.53, p=0.0037) for CVD and for
stroke: 12.28 (CI: 1.48-101.77, p=0.02). IgG aOxCL levels did not differ between quartiles in CVD-risk. High levels of
IgM aOxCL (reaching significance above 86th) and IgG aOxCL (above 95th percentile) were associated with
decreased risk of CVD (OR: 0.485, CI: 0.283-0.829; p=0.0082 and OR: 0.23, CI: 0.07-0.69; p=0.0091). aCL were not
associated with CVD. oxCL but not CL competed out uptake of OxLDL in macrophages, and aOxLDL recognized
oxCL but not CL. In contrast to aCL, aOxCL was not dependent on co-factor Beta2-glycoprotein-I.
Conclusions: aOxCL is a novel risk/protection marker for CVD, with therapeutic implications. OxCL competes with
oxLDL for uptake in macrophages and the possibility that aOxCL inhibits such uptake by interfering with same or
similar epitopes in oxCL and oxLDL should be further studied.
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Atherosclerosis is the major underlying cause of cardio-
vascular disease (CVD) as stroke and myocardial infarc-
tion (MI) and can be regarded as an inflammatory
disease, where activated immune competent cells produ-
cing cytokines are typical features [1]. However, trad-
itional risk factors as age, male sex, hypertension,
hyperlipidemia, smoking and diabetes do not account* Correspondence: johan.frostegard@ki.se
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reproduction in any medium, provided the orfor the inflammatory nature of atherosclerosis. There-
fore, novel risk markers are needed which account for
inflammation and immune reactions related to athero-
sclerosis and CVD. High sensitivity C-reactive protein
(hsCRP) has been much discussed and is of major inter-
est in CVD [2]. However, the volatility of this measure
may be a limitation when hsCRP is used at the individ-
ual level. LDL-PLA2 is another interesting emerging in-
flammatory risk marker [3]. We have recently reported
that natural antibodies against phosphorylcholine of IgM
subclass (anti-PC) could be of interest, since low levels
of these antibodies in several studies were associatedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ies in atherosclerosis and CVD were not developed to
target the inflammatory and immunological nature of
these conditions, also therapies with anti-inflammatory
and/or immune modulatory properties are needed.
CL is a phopholipid with a unique double phospho-
lipid, containing four fatty acid chains. CL is found pri-
marily in the inner mitochondrial membrane of
euraryotic cells and in bacteria [9] which is interesting
to note since mitochondria are believed to have a bacter-
ial origin from an evolutionary point of view [10]. CL
plays a central role in mitochondrial bioenergetics and
also appears to be of major importance in apoptosis and
membrane dynamics [9].
Antibodies against CL (anti-CL) are generally recog-
nized as risk factors for thrombosis, both venous and ar-
terial, especially in patients with rheumatic diseases like
systemic lupus erythematosus (SLE) [11].
To the best of our knowledge, the clinical role of anti-
bodies against oxidized CL (OxCL) has not been
described previously. We here report that anti-OxCL in
contrast to anti-CL is negatively associated with CVD:
low levels being associated with increased risk and high




From July 1st 1997 to June 30th 1998, every third man
and woman living in the County of Stockholm reaching
the age of 60 years, were invited to participate in a
health screening for cardiovascular diseases. By this se-
lection of individuals, age bias was avoided. A total num-
ber of 4232 subjects (2039 men and 2193 women;
response and rate 78%) participated in the investigation.
Information on sociodemography, lifestyle habits, medi-
cation and previous diseases and hospitalizations was
obtained by a self-administered questionnaire. Physical
examination with blood pressure measurements, anthro-
pometry and ECG was performed and serum, plasma
and whole blood were collected for storage in a bio-
logical bank (−80°C). Details of the screening procedure
have been given elsewhere [12,13]. The study was
approved by the Karolinska Institutet research ethics
committee and is in accordance with the Helsinki Dec-
laration. All subjects gave written informed consent be-
fore entering the study.
A nested case–control design
To record incident cases of first CVD, new events of coron-
ary heart disease (CHD), defined as fatal and non-fatal myo-
cardial infarction (MI) and ischemic stroke, hospitalization
for angina pectoris, were registered. The study base of 4232
subjects was matched with the national cause of deathregistry (fatal events until December 31, 2003) and the na-
tional in-hospital registry (non-fatal events until December
31, 2005 ). Through these matching procedures 211 incident
cases of CVD were recorded. To guarantee that first CVD
events were registered, only subjects without a history of
CVD prior to recruitment were utilized for the matching
procedures. The International Classification of Diseases
(ICD-10) was used to register CHD-deaths (I 20, I 21, I 46),
MI (I 21), angina pectoris including PCIs and CABGs (I 20,
Z 95.5 and Z 95.1) and ischemic stroke (I 63-I 66). The cri-
teria used were thus uniform and consistent. For each case
three controls were randomly selected, matched for gender
and age (+/− 60 days). Thus, a nested case–control design
(211 cases and 633 controls) was applied for the epidemio-
logical and statistical analyses.Oxidation of CL
CL from bovine heart was purchased as ethanol solution
from Sigma (Sigma product C 1649) and was stored at
−20°C. To generate saturated molecular species, cardioli-
pin was oxidized in aqueous solutions containing 1.5
mmol/L tert-butylhydroperoxide and CuSO4 in 20
μmol/L. Both CL and thus treated CL were measured
with mass spectrometry (Electrospray ionization mass
spectrometer (Micromass, Beverly, MA, USA), to con-
firm that CL had been oxidized by copper and tert-
butylhydroperoxide.Determination of antibodies against CL and OxCL with
ELISA
IgM and IgG antibodies to OxCL were determined by
enzyme-linked immunosorbent assay (ELISA). serum
from two donors with anti-OxCL levels above median
levels were used as internal standard and tested on every
plate. The plateau of antibody binding was reached with
the antigen concentration of 10 μg/ml. Immulon 1B
plates (Thermo Labsystems, Franklin, MA, USA) were
coated with oxidized cardiolipin (OxCL) (10 μg/ml)
50 μl/well in ethanol. Coated plates were incubated over-
night at 4°C. After five washings with PBS, the plates
were blocked with 2% BSA-PBS for 2h at room
temperature and washed as described above. Serum
samples were diluted (1:50) in 0.2% BSA-PBS and added
at 50 μl/well.
Plates were incubated overnight at 4°C and washed as
described above. Alkaline phosphatase conjugated goat
anti-human IgM or IgG (diluted 1:7000 in the sample
buffer) were added at 100 μl/well and incubated at 4°C
overnight. After five washings, color was developed by
adding the alkaline phosphatase substrate (PNPP) at
100μl/well and incubating the plates for 60 min at room
temperature in the dark. The plates were read in an
ELISA Multiscan Plus spectrophotometer at 405 nm. All
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the coefficient of variation was below 10%.
IgM and IgG antibodies to CL where measured by a
standard ELISA kit (Orgentec diagnostika GmbH,
Mainz, Germany) according to the manufacturers
description.
In order to investigate the specificity of anti-OxCL, com-
petition assays were performed. At a dilution giving 50% of
maximal binding to anti-OxCL, sera were preincubated with
different concentrations of OxCL or CL coated overnight
onto glass tubes. After vortexing, the tubes were incubated
at 4°C overnight and centrifuged at 13000 r.p.m. for 30 min
(4°C). The supernatants were tested for antibody binding to
OxCL as described.Figure 1 Electrospray ionization mass MS spectrometer (Micromass, B
oxidized.To test effects of aOxLDL, sera were pre-incubated with
different concentrations of OxLDL (Intracel, Frederick,
Maryland) at 4°C overnight and centrifuged at 13000 r.p.m.
for 30 min (4°C). The supernatants were tested for antibody
binding to OxLDL, OxCL and CL.
The percentage of inhibition was calculated as follows:
Percent inhibition = (OD without competitor – OD
with competitor)/OD without competitor × 100
Effect of ß2GPI on the binding of anti-OxCL or anti-CL
with ELISA
The assay was essentially performed as described above for
the anti-OxCL or anti-CL ELISA. Plates were coated with
OxCL or CL, blocked with 2% BSA-PBS, then incubatedeverly, MA) was used to demonstrate that cardiolipin was
Figure 2 a Competition ELISA of IgM anti-OxCL binding to plated OxCL in the absence or presence of indicated amounts of OxCL or
CL preincubated with sera. The results are expressed as Percent inhibition = (OD without competitor - OD with competitor)/ OD without
competitor X100. Each value shown is the mean±standard deviation. b ELISA of IgM anti-OxCL or anti-CL which had been postincubated with
different concentration of ß2GP1 (for 1 hour at RT). ß2GPI could increase anti-CL binding to CL but not anti-OxCL binding to OxCL. The results are
expressed as mean±standard deviation. c Competition ELISA of binding of IgM anti-OxCL, anti-CL and aOxLDL respective antigens after
preincubation with the indicated concentrations of oxLDL.. The results are expressed as Percent inhibition = (OD without competitor - OD with
competitor)/ OD without competitor X100. Each value shown is the mean±standard deviation. d Competition ELISA of binding of IgM anti-OxCL
and anti-PC to respective antigens after preincubation with the indicated concentrations of PC-BSA. The results are expressed as Percent
inhibition = (OD without competitor - OD with competitor)/ OD without competitor X100. Each value shown is the mean±standard deviation.
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sera from high-titer patients from patients with the antipho-
spholipid antibody syndrome (APS) for 1h at room
temperature. Each value shown is the mean±standard
deviation.
Inhibition of macrophage uptake of oxLDL
oxLDL prepared by incubation with CuSO4 (Intracel, Fred-
erick, US) was incubated with Dil (Molecular Probes
Engene, Oregon, USA) in lipoprotein-deficient serum
(Sigma) at 37°C for 15 hours. Then the mixture was dialyzed
against saline-EDTA buffer for 6 hours.
The macrophages differentiated from THP-1 cells were
plated in a 24-well plate (NUNC Inc, Naperville, Ill) atdensity of 3 × 105 cells/well in DMEM (INVITROGEN,
USA) containing 10% FBS overnight. Then the cells were
incubated with Dil-oxLDL (5 μg/ml), with oxCL (7,
10 μg/ml), with CL control (7, 10 μg/ml) for 4 hours. There-
after, the cells from above were washed 4 times with 0.2%
BSA/PBS and once with PBS. The cells were harvested in
PBS containing 0.1% BSA and 0.01% NaN3. Uptake of Dil-
labelled oxLDL was studied by Flow cytometry and a mini-
mum of 10.000 cells was analyzed.
Determination of estimated glomerular filtration (eGFR)
and risk score
As a measurement of GFR, we used the estimated GFR
(eGFR) using the CKD-EPI formula [14]. For determination
Table 1 Baseline characteristics among incident CVD cases and matched controls
Incident cases Controls P value
Number 211 633 NA
Age, years 60 60 NA
Male gender, % 66.4 66.4 NA
Smokers, % 31.9 19.6 0.0002
Diabetes % 24.3 15.7 0.005
BMI kg/m2 27.7 ±4.6 26.7 ±3.8 0.0031
Hypertension (>140/90 mm Hg ), % 42.4 25.6 <0.0001
Glucose mmol/L 6.1 ±2.5 5.6 ±1.5 0.0004
Insulin μmol/L 11.4 ±7.1 10.2±6.5 0.0317
Systolic blood pressure, mm Hg 148 ±21.8 139 ±21.2 <0.0001
Diastolic blood pressure, mm Hg 98 ±10.6 85 ± 10.4 <0.0001
Cholesterol, mMol/l 6.1 ±1.0 6.0 ±1.2 0.14
HDL, mMol/l 1.3 ±0.4 1.4 ±0.4 0.0005
LDL, mMol/l 3.9 ±1.2 3.8 ±1.1 0.45
Triglycerides, mMol/l 1.6 ±1.0 1.4 ±0.8 0.0005
hsCRP, mg/l 2.4 (1.3-4.7) 1.7(0.9-3.2) <.0001
eGFR 90.5 (81.4-106.0) 90.9 (80.4-103.9) 0.73
Framingham Risk Score 14.5±2.3 13.5±2.0 <0.0001
IgM anti-OxCL U/ml, men and women. 88.97(68.36-114.6) 96.90(72.56-123.44) 0.024
IgM anti-OxCL U/ml , men. 84.16(63.38-112.57) 96.90(70.35-123.10) 0.0047
IgM anti-OxCL U/ml , women. 99.06(78.04-123.70) 96.75(74.07-124.37) 0.78
IgM anti-CL U/ml, men and women. 1.87(1.34-3.00) 2.02(1.38-3.12) 0.34
Data are presented as percentage, mean ± SD, or median with interquartile ranges within paranthesis.
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[15].
Statistics
Demographic data, biochemistry and anthropometry were
performed for cases and controls respectively with values
expressed as mean ± standard deviations (SD) for normally
distributed parameters and medians (ranges) or proportions
for parameters which were not normally distributed after
logarithmic transformation. Statistical differences between
cases and controls were assessed through non-parametric
tests. Odds ratios (OR) with 95% confidence intervals (CI )
were calculated applying conditional logistic regression.
Analyses were run crude or adjusted for traditional risk fac-
tors as indicated. Receiver operating characteristic (ROC)
curves and the area under those curves (AUC) for stroke
prediction with and without anti-PC were calculated.Table 2 Association between levels of IgM anti-OxCL and risk
anti-OxCL Crude
Quartiles (U/ml) cases controls OR
Quartile 4 122.16> 41 165 1
Quartile 3 94.99< <=122.16 55 151 1.47
Quartile 2 70.65 <=94.99 52 154 1.41
Quartile 1 <=70.65 61 145 1.75Statistical analyses were run with SASWstatistical soft-
ware system version 9.1.Results
CL-oxidation by copper and tert-butylhydroperoxide
was confirmed by mass spectrometry (Figure 1). Prein-
cubation with OxCL could inhibit up to 60-70% of IgM
anti-OxCL binding to OxCL while CL (exposed to air
over night had low capacity to influence anti-OxCL
binding (Figure 2a). Further, ß2GPI, a co-factor for anti-
CL, could induce increased anti-CL binding to CL but
not anti-OxCL binding to OxCL (Figure 2b).
OxLDL competed out IgM antibody binding to oxCL
but effects on binding to CL were negligible (Figure 2c).
PC-BSA competed out IgM antibody binding to PC-BSA
but not to oxCL (Figure 2d).for MI and/or + stroke (CVD), men and women
Adjust
95% CI P-values OR 95% CI P-values
N/A NA 1 N /A N /A
0.93 2.33 0.099 1.58 0.98 2.55 0.059
0.88 2.26 0.16 1.43 0.88 2.33 0.15
1.10 2.79 0.018 1.80 1.12 2.91 0.016
Table 3 Association between levels of IgM anti-OxCL and MI and/or + stroke (CVD), men
anti-OxCL Crude Adjust
Quartiles (U/ml) cases controls OR 95% CI P-values OR 95% CI P-values
Quartile 4 122.16> 23 107 1 NA NA 1 NA NA
Quartile 3 94.99< <=122.16 35 107 1.52 0.85 2.73 0.16 1.66 0.90 3.06 0.11
Quartile 2 70.65 <=94.99 33 97 1.65 0.89 3.06 0.11 1.80 0.94 3.42 0.075
Quartile 1 <=70.65 48 104 2.22 1.24 3.98 0.0070 2.46 1.34 4.53 0.0037
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throughout the follow-up period (77 with MI, 85 with
angina pectoris and 49 with ischemic stroke). For each
incident case three age and sex matched controls were
selected, and thus 633 controls. Serum samples were
missing for 2 case and 18 controls leaving 209 cases and
615 controls for analyses.
As previously reported, there were more smokers and
hypertensives among cases than controls and trendwise
higher BMI. Further, blood pressure levels, blood lipids,
hCRP and apoproteins were less favourable among cases
as compared to controls (Table 1).
Median values and interquartile ranges for IgM anti-
OxCL indicated lower values among incident cases than
controls, a difference particularly apparent in men where
incident cases had significantly lower median values as
compared to controls, (Table 1).
The association between anti-OxCL and risk of CVD indi-
cates an excess risk for those within the lowest quartile of
anti-OxCL values compared with subjects within quartile 4
(set as the reference group, OR = 1.0). Even though OR in
quartile 2 and 3 were also raised, this difference did not
reach statistical significance. Also after adjustment for smok-
ing, BMI, type II diabetes, hypercholesterolaemia, and high
blood pressure a significantly increased relative risk (OR) for
CVD was determined in the lowest quartile of anti-OxCL
(Tables 2, 3, and 4).
If the highest 25th percentile of IgM aOxCL were com-
pared with the other three lower percentiles, the risk of the
lower three was raised significantly for the whole group
(crude: OR 1.54, CI 1.04-2.28, p=0.031; adjusted OR 1.60, CI
1.07-2.40, p= 0.022). These associations also reached signifi-
cance for men (crude: OR 1.77, CI 1.07-2.57, p=0.025;Table 4 Association between levels of IgM anti-OxCL and MI
anti-OxCL Crud
Quartiles (U/ml) cases controls OR
Quartile 4 122.16> 18 58 1
Quartile 3 94.99< <=122.16 20 44 1.49
Quartile 2 70.65 <=94.99 19 57 1.14
Quartile 1 <=70.65 13 41 1.04
*The OR and the P-values for each quartile are compared to quartile 4.adjusted OR 1.94, CI 1.15-3.30, p= 0.014) but not for
women (data not shown).
If the lowest 25th percentile of IgM aOxCL were com-
pared with the other three higher percentiles, the risk of the
lower was raised trendwise for the whole group (crude: OR
1.36, CI 0.95-1.95, p=0.090; adjusted OR 1.37, CI 0.94-1.98,
p= 0.10). These associations reached significance for men
(crude: OR 1.59, CI 1.05-2.43, p=0.030; adjusted OR 1.606,
CI 1.07-2.57, p= 0.024) but not for women (data not
shown).
Women in the highest quartile were significantly pro-
tected against MI (data not shown).
High levels of IgM anti-OxCL, adjusted for smoking,
BMI, type II diabetes, hypercholesterolaemia, and high
blood pressure (reaching significance above 86th per-
centile) were associated with significantly decreased risk
(OR: 0.485, CI 0.0.283-0.829; p=0.0082).
Further adjustements for hsCRP gave essentially similar
OR for IgM anti-OxCL (data not shown). Regarding co-
morbidities such as autoimmune diseases, there were 10
individuals with Rheumatoid Arthritis. These did not differ
significantly from others in antibody levels (data not shown).
There were no significant associations between IgM
anti-CL and CVD in our study (data not shown). How-
ever, trendwise, very high anti-CL levels were associated
with increased risk of CVD among men, and above
highest 98th percentile OR was 2.37 for women, (non-
significant).
There were no significant differences between cases
and control in levels of anti-OxCL or anti-CL, when me-
dian levels where compared (data not shown).
High levels of IgG anti-OxCL (above 95th percentile),
adjusted for smoking, BMI, type II diabetes,and/or + stroke (CVD), women
e Adjust
95% CI P-values OR 95% CI P-values
N/A N /A 1 NA NA
0.70 3.20 0.30 1.67 0.76 3.67 0.20
0.54 2.42 0.72 1.14 0.52 2.47 0.75
0.45 2.40 0.92 0.99 0.42 2.32 0.97
Table 5 Association between levels of IgG anti-OxCL and risk for MI and/or + stroke (CVD), men and women
aOxC.IGG Crude Adjust
Quartiles (U/ml) cases controls OR 95% CI P-values OR 95% CI P-values
Quartile 4 80.81> 53 155 1 N/A NA 1 N /A N /A
Quartile 3 59.66< <=80.81 49 156 0.89 0.57-1.39 0.62 0.95 060-1.51 0.83
Quartile 2 44.13< <=59.66 55 153 1.05 0.67-1.63 0.84 1.26 0.79-2.02 0.33
Quartile 1 44.13<= 52 151 0.99 0.63-1.54 0.95 1.11 0.70-1.77 0.65
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associated with strikingly and significantly decreased risk
(OR=0.23: CI 0.07-0.69; p=0.0091).
There were no significant associations between IgG
anti-CL and CVD in our study (Tables 5, 6 and 7). Fur-
ther, very high IgG anti-CL levels, above 98th percentile
(as in the antiphospholipid antibody syndome) were not
associated with increased risk of CVD (OR=0.94,
CI=0.29-3.09 P=0.9206).
The AUC of ROC curves accounting for traditional
risk factors (hypertension, diabetes, hypercholesterol-
emia, smoking and BMI) was 0.63 for the whole study
group, 0.63 for men and 0.65 for women. Adding IgM
anti-OxCL (with cut-off below 25th percentile) to this
model gave AUC of 0.64 for the whole group, 0.64 for
men and 0.66 for women. the increase among men was
significant in the maximum likelihood ratio test
(p=0.02).
To study further potential mechanisms of oxCL bio-
activity, 1×106/ well THP-1 differentiated macrophages
were used for uptake studies. oxLDL could inhibit dil-
OxLDL uptake up to more than 60%, but LDL hade al-
most no effect on the uptake of dil-oxLDL which con-
firmed the specificity of uptake results. Further results
indicate that oxCL can, in a concentration dependent
manner, inhibit dil-oxLDL uptake while the native CL
did not show the competition effects (Figure 3).
Discussion
The main finding in this study is that IgM antibodies
against oxidized cardiolipin are negatively associated
with risk for development of CVD. Individuals (men and
women) with low levels of anti-OxCL (below lowest
quartile) had an almost 2-fold increased risk, independ-
ent of other risk factors. Further, high levels of IgM anti-Table 6 Association between levels of IgG anti-OxCL and MI a
anti-OxCL.IGG Cru
Quartiles (U/ml) cases controls OR
Quartile 4 80.81> 38 111 1
Quartile 3 59.66< <=80.81 34 111 0.89
Quartile 2 44.13 < <=59.66 41 100 1.21
Quartile 1 44.13<= 26 93 0.83OxCL were protective: values above 86th percentile were
associated with a more than 50% reduction of risk of
CVD. The associations were especially striking for men;
when analysed separately, the risk of development of MI
was almost 2.5 in the lowest quartile and even though
stroke cases were relatively few, it is interesting to note
that the risk of stroke was 12-fold for men with anti-
OxCL in the lowest quartile (though confidence intervals
were high). In addition, men who within 5–7 years
developed CVD had significantly lower median values at
baseline than men who did not. There were also signifi-
cant associations for women, where a two-fold risk for
MI was noted below the highest quartile of anti-OxCL
levels.
Further, we report that IgG anti-OxCL were not asso-
ciated with CVD when divided in quartiles, however,
very high antibody levels were indeed strong protection
markers, with a decreased risk of CVD (OR of 0.23
above 95th percentile).
CL is abundant in the environment of mitochondrial
oxidative burst, and is easily oxidized due to its unsatur-
ated double bonds [16,17]. Further, it was demonstrated
that cardiolipin is the only phospholipid in mitochondria
undergoing early oxidation during apoptosis, by a
cardiolipin-specific peroxidase activity of cardiolipin-
bound cytochrome c [18,19]. Oxidized cardiolipin is
needed for release of proapoptotic factors and thus may
play a role in induction of apoptosis, eg through effects
on release of cytochrome c, since cytochrome c anchor-
age in mitochondria depends on CL, and CL loss and/or
oxidation can induce detachment and release, leading to
apoptosis [18–20]. Though the OxCL studied herein is
extensively oxidized it is thus still possible that similar
forms of OxCL are present in vivo. The non-mutually
exclusive possibility that enzymes such as phospholipasend/or + stroke (CVD), men
de Adjust
95% CI P-values OR 95% CI P-values
NA NA 1 NA NA
0.53-1.50 0.66 0.98 0.56-1.69 0.93
0.72-2.03 0.47 1.45 0.84-2.51 0.18
0.47-1.45 0.51 0.94 0.53-1.68 0.83
Table 7 Association between levels of IgG anti-OxCL and MI and/or + stroke (CVD), women
anti-OxCL.IGG Crude Adjust
Quartiles (U/ml) cases controls OR 95% CI P-values OR 95% CI P-values
Quartile 4 80.81> 15 44 1 N/A N /A 1 NA NA
Quartile 3 59.66< <=80.81 14 45 0.90 0.38-2.11 0.81 0.92 0.37-2.19 0.82
Quartile 2 44.13< <=59.66 14 53 0.76 0.32-1.82 0.54 0.96 0.39-2.38 0.93
Quartile 1 44.13<= 26 58 1.22 0.55-2.69 0.63 1.39 0.60-3-20 0.44
*The OR and the P-values for each quartile are compared to quartile 4.
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LDL-modification) is also interesting and deserves fur-
ther studies.
Our findings are comparable with our recent observa-
tions on another phospholipid-related epitope, phos-
phorylcholine (PC). We have reported that antibodies to
PC (anti-PC) are negatively associated with CVD and
atherosclerosis, with the most striking observations at
low levels, which are associated to increased risk of
CVD [5–8,21] while high levels are associated with a
favourable development with less atherosclerosis [22]. It
should be noted that PC is not present in CL (and thus
not in OxCL) and further, cross reactivity between these
antigens was relatively low (unpublished observation). In
contrast to anti-PC, anti-OxCL was a protective factor
for CVD at high levels, since high levels were associated
with a 50% decreased risk.
In an interesting report it was demonstrated that CL is
quickly oxidized when coated on ELISA-plates for deter-
mination of anti-CL and many anti-CL may recognize
this variant of OxCL which could contribute to the anti-
phospholipid antibody syndrome [17]. Further, this formFigure 3 Effect of OxCL on macrophage uptake of OxLDL. The
histograms depict differences in fluorescence intensity of Dil-OxLDL
taken up by macrophages with 5ug/ml of CL or OxCL, indicating
that OxCL but not CL decreases the uptake of OxLDL. Yellow
represents control with no addition of lipid or other compound.of CL, oxidized by exposure to air, had ß2GPI as a co-
factor [23]. Interestingly, ß2GPI does not appear to play
a role in antibody binding to OxCL. However, we cannot
exclude that other protein-OxCL complexes could play a
role, but if so, the antigen is not recognized by atherotr-
hombogenic antibodies.
The nature of the antigen recognized by anti-CL is still
debated, almost three decades after their discovery [24],
but there are many studies indicating that the plasma
co-factor ß2GPI increases the binding to CL and plays a
role in the antigenicity and also thrombogenicity.
The oxCL we used did not show a high cross-
reactivity with CL as antigen. The commercial kit used
herein for determination of antibodies against CL is
developed to detect native CL. In contrast to IgM anti-
OxCL, IgM anti-CL was not significantly associated with
CVD either negatively or positively in the whole study
group, though among men, median level of anti-CL IgM
was lower among cases. However, there were trendwise
associations between high IgM anti-CL-levels and
increased risk of CVD among men and almost threefold
but non-significant risks for women, when the highest
percentiles were studied. Further, IgG anti-CL (which in
general is believed to be more prothrombotic than IgM
[11]), were not associated with CVD, not even trendwise.
Whether some of the anti-OxCL binding to OxCL are
present in immune complexes is an interesting possibil-
ity, which is beyond the scope of the present paper,
which focused on the totality of oxCL binding
antibodies.
The role of anti-CL in the general population is not
clear, though such antibodies may play a role in sub-
groups as in survivors of MI (below 45 years of age)
[25]. In one study on recurrent coronary events among
patients with a history of MI, high IgG anti-CL, but also,
interestingly, low IgM anti-CL were associated with
increased risk [26]. In our study of 60-year olds with no
history of MI or CVD, we did not determine such asso-
ciations and determinations also of anti-OxCL in
patients with a history of MI and/or CVD are clearly of
interest. However, it appears likely that anti-CL mainly
plays a role as a risk factor for CVD (including both ar-
terial and venous thrombosis) in systemic rheumatic dis-
eases like SLE where such antibodies are strong risk
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with a history of CVD.
To identify mechanisms which could explain the pro-
tective role of anti-OxCL, we determined interactions
with oxLDL, a major factor in atherosclerosis. OxLDL
could inhibit antibody binding to oxCL but not to CL,
which indicates cross reactivity. In an interesting previ-
ous report, it was demonstrated that aOxLDL cross react
with anti-CL [28]. The most likely explanation to this
difference is that CL is to some extend oxidized during
the incubation used in that publication [17]. The finding
that oxLDL cross reacts with oxCL could have several
implications. Since CL is present in LDL [29], our find-
ing most likely indicates that oxCL is a component of
oxLDL. We recently demonstrated that oxCL but not
CL is pro-inflammatory (unpublished observation) and
one possibility is therefore that anti-OxCL is anti-
inflammatory.
We demonstrated herein is that oxCL but not CL inhi-
bits uptake of oxLDL in macrophages. OxLDL is taken
up through specific scavenger receptors, which are not
down-regulated when exposed to increasing amounts of
oxLDL (as opposed to the uptake of LDL). Inhibition of
the scavenger function is generally believed to be athero-
protective, preventing foam cell formation in the vascu-
lar wall which is a key process in development of
atherosclerosis. In line with this, mice defective in scav-
enger receptor function develop less atherosclerosis [30].
Binding and uptake of oxLDL through oxCL could thus
promote atherogenesis.
It should be noted, however, that recent research indi-
cates that different scavenger receptors may play differ-
ent roles and the role of scavenger receptors may vary
depending on disease stage and type [31].
It has previously been demonstrated that murine
monoclonal IgM recognizing forms of ox-CL can dis-
criminate apoptotic cells from healthy cells [32]. Further,
natural IgM binding to apoptotic cells increase apoptotic
cell phagocytosis and also have direct anti-inflammatory
properties [33]. It is possible that natural IgM including
anti-PC and aOxCL could counter atherosclerosis devel-
opment by increasing phagocytosis of dead and dying
cells in the lesions.
It is interesting to note that the associations here were
independent on traditional risk factors, and also hsCRP.
Further, presence of hypertension in combination with
low anti-OxCL increased the risk.
Conclusions
Low anti-OxCL could be developed into a method to
identify individuals at risk of CVD where intensified
established treatment could be of importance, a possibil-
ity that further studies are needed to confirm. In the fu-
ture, immunomodulation to raise levels of anti-OxCLthrough active or passive immunisation could be of
interest.
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